MPMark B. Pepys

Mark B. Pepys

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark B. Pepys has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Glenys A. Tennent

    Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London Medical School, London NW3 2PF, United Kingdom

    5 shared publications
  • J. Ruth Gallimore

    Centre for Amyloidosis and Acute Phase Proteins and the National Amyloidosis Centre, Division of Medicine (Royal Free Campus), University College London Medical School, London NW3 2PF, United Kingdom

    4 shared publications
  • Philip N. Hawkins

    Centre for Amyloidosis and Acute Phase Proteins and the National Amyloidosis Centre, Division of Medicine (Royal Free Campus)

    4 shared publications
  • Carol Vivien Robinson

    Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford, UK

    3 shared publications
  • Caroline Anne Sabin

    Institute for Global Health, University College London, London, UK

    3 shared publications
  • Melvyn C. Kahan

    Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK

    3 shared publications

Latest Publications

  • Trapping of palindromic ligands within native transthyretin prevents amyloid formation

    by Simon E. Kolstoe, Palma P. Mangione, Vittorio Bellotti, Graham W. Taylor, Glenys A. Tennent, Stéphanie Deroo, Angus J. Morrison, Alexander J. A. Cobb, Anthony Coyne, Margaret G. McCammon, et al.

    Transthyretin (TTR) amyloidosis is a fatal disease for which new therapeutic approaches are urgently needed. We have designed two palindromic ligands, 2,2'-(4,4'-(heptane-1,7-diylbis(oxy))bis(3,5-dichloro-4,1-phenylene)) bis(azanediyl)dibenzoic acid (mds84) and 2,2'-(4,4'-(undecane-1,11-diylbis(oxy))bis(3,5-dichloro-4,1-phenylene)) bis(azanediyl)dibenzoic acid (4ajm15), that are rapidly bound by native wild-type TTR in whole serum and even more avidly by amyloidogenic TTR variants. One to one stoichiometry, demonstrable in solution and by MS, was confirmed by X-ray crystallographic analysis showing simultaneous occupation of both T4 binding sites in each tetrameric TTR molecule by the pair of ligand head groups. Ligand binding by native TTR was irreversible under physiological conditions, and it stabilized the tetrameric assembly and inhibited amyloidogenic aggregation more potently than other known ligands. These superstabilizers are orally bioavailable and exhibit low inhibitory activity against cyclooxygenase (COX). They offer a promising platform for development of drugs to treat and prevent TTR amyloidosis.


  • Open Access

    Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis

    by Julian D. Gillmore, Glenys A. Tennent, Winston L. Hutchinson, Janet Ruth Gallimore, Helen J. Lachmann, Hugh J.B. Goodman, Mark Offer, David J. Millar, Aviva Petrie, Philip N. Hawkins, et al.

    Summary: Serum amyloid P component (SAP) is a universal constituent of amyloid deposits and contributes to their formation and/or persistence. We therefore developed CPHPC ((R)‐1‐[6‐[(R)‐2‐carboxy‐pyrrolidin‐1‐yl]‐6‐oxo‐hexa‐noyl]pyrrolidine‐2 carboxylic acid), a novel bis(D‐proline) drug, to specifically target SAP and report here a first, exploratory, open label proof of principle study in systemic amyloidosis. CPHPC produced sustained, >95% depletion of circulating SAP in all patients and c. 90% reduction in the SAP content of the two amyloidotic organs that became available. There were no significant adverse effects of either SAP depletion or CPHPC itself. No accumulation of amyloid was demonstrable by SAP scintigraphy in any patient on the drug. In hereditary fibrinogen amyloidosis, which is inexorably progressive, proteinuria was reduced in four of five patients receiving CPHPC and renal survival was prolonged compared to a historical control group. These promising clinical observations merit further study.


  • Open Access

    Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis

    by Francesco Carlucci, H. Terence Cook, Abhilok Garg, Mark B. Pepys, Marina Botto

    Objective It has been reported that a single dose of human C‐reactive protein (CRP) can prevent and reverse the renal damage in murine models of spontaneous lupus, as well as the rapid‐onset immune complex disease induced in the accelerated nephrotoxic nephritis (ANTN) model. This study was undertaken to attempt to replicate these observations using a highly purified and fully characterized human CRP preparation. Methods (NZB × NZW)F1 (NZB/NZW) mice were treated with a single 200‐μg subcutaneous injection of CRP or control reagents either before disease onset at 4 months of age or when high‐grade proteinuria was present at 7 months of age. Mice were monitored at least monthly for proteinuria and autoantibody levels. ANTN was induced by preimmunizing C57BL/6 mice with sheep IgG, followed 5 days later by injection of sheep anti‐mouse glomerular basement membrane antibody and CRP or control reagents. Renal disease was assessed by regular urinalysis and histologic evaluation. Results CRP treatment of NZB/NZW mice, either early or late in the disease, had no effect on proteinuria, autoantibody titers, or survival. CRP administration did not reduce renal injury or alter disease in the ANTN model. Human serum amyloid P component, a pentraxin protein that is very closely related to CRP, similarly had no effect. Conclusion Our completely negative observations do not confirm that human CRP has reproducible antiinflammatory or immunomodulatory effects in these murine models, nor do they support the suggestion that CRP might be useful for therapy of lupus or immune complex–mediated nephritis.


  • Open Access

    Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component

    by Simon E. Kolstoe, Basil H. Ridha, Vittorio Bellotti, Nan Wang, Carol V. Robinson, Sebastian J. Crutch, Geoffrey Keir, Riitta Kukkastenvehmas, J. Ruth Gallimore, Winston L. Hutchinson, et al.

    New therapeutic approaches in Alzheimer's disease are urgently needed. The normal plasma protein, serum amyloid P component (SAP), is always present in cerebrospinal fluid (CSF) and in the pathognomonic lesions of Alzheimer's disease, cerebrovascular and intracerebral Aβ amyloid plaques and neurofibrillary tangles, as a result of its binding to amyloid fibrils and to paired helical filaments, respectively. SAP itself may also be directly neurocytotoxic. Here, in this unique study in Alzheimer's disease of the bis(d-proline) compound, (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC), we observed depletion of circulating SAP and also remarkable, almost complete, disappearance of SAP from the CSF. We demonstrate that SAP depletion in vivo is caused by CPHPC cross-linking pairs of SAP molecules in solution to form complexes that are immediately cleared from the plasma. We have also solved the structure of SAP complexed with phosphothreonine, its likely ligand on hyperphosphorylated τ protein. These results support further clinical study of SAP depletion in Alzheimer's disease and potentially other neurodegenerative diseases.


  • A molecular correlate of clinicopathology in transthyretin amyloidosis

    by Mark B Pepys

    The mechanisms responsible for amyloid deposition at different times and in different organs, even in individuals with the same amyloidogenic mutation, are not known. The demonstration, in hereditary systemic transthyretin Val30Met amyloidosis, that such differences are consistently associated with amyloid fibrils composed of different length transthyretin fragments sheds new light on this question and will open the way to further informative studies. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • C‐reactive protein and coronary heart disease: a critical review

    by J. P. Casas, T. Shah, A. D. Hingorani, J. Danesh, M. B. Pepys

    : Modestly elevated baseline concentrations of C‐reactive protein (CRP), the classical acute phase protein, are associated with the long‐term risk of coronary heart disease in general populations, whilst the major acute phase response of CRP following myocardial infarction is associated with death and cardiac complications. The pathogenic and clinical significance of these associations is controversial. Here we critically review the evidence and describe large‐scale epidemiological studies, novel experiments and possible specific therapies which will rigorously inform the debate. We distinguish between the potential pathogenicity of high acute phase circulating CRP concentrations in individuals with substantial tissue damage and modest but persistent increases in baseline values in generally healthy subjects.


  • Open Access

    Science and serendipity

    by Mark B Pepys

    Good science demands independent replication of new ideas and results and abandonment of accepted theories in light of more reliable evidence. Failure to comply leads to damaging bad science, as with the falsely claimed association between measles, mumps and rubella vaccination and autism. Progress of good science also often requires serendipity, ‘making discoveries by accident and sagacity of things not sought’. Work on the pentraxin proteins, C-reactive protein (CRP) and serum amyloid P component (SAP), and on amyloidosis, has benefited from abundant serendipity, leading to routine clinical use of CRP measurements, the invention of SAP scintigraphy for amyloidosis, the establishment of the NHS National Amyloidosis Centre providing superior patient care, and latterly the invention of a novel pharmacological mechanism for therapeutic depletion of pathogenic proteins. New drugs using this mechanism are in development for amyloidosis and cardiovascular disease and potentially also Alzheimer's disease, type II diabetes and other tissue damaging conditions.


  • Is leptin an important physiological regulator of CRP?

    by Winston L Hutchinson, Anthony P Coll, J Ruth Gallimore, Glenys A Tennent, Mark B Pepys